Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Transcode Therapeutics Inc (NQ: RNAZ )

0.4993 -0.0047 (-0.93%)
Streaming Delayed Price Updated: 9:40 AM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 41,630
Open 0.4917
Bid (Size) 0.4907 (6)
Ask (Size) 0.4994 (5)
Prev. Close 0.5040
Today's Range 0.4917 - 0.5000
52wk Range 0.2160 - 19.42
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
From TransCode Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga

Performance

YTD
-92.27%
-92.27%
1 Month
-12.56%
-12.56%
3 Month
+78.32%
+78.32%
6 Month
-20.72%
-20.72%
1 Year
-96.63%
-96.63%

More News

Read More
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
From TransCode Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
From TransCode Therapeutics, Inc.
Via GlobeNewswire
RNAZ Stock Earnings: TransCode Therapeutics Misses EPS for Q2 2024
Via InvestorPlace
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
TransCode Therapeutics, Inc. Announces Closing of Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Gold Moves Higher; Coca-Cola Increases FY24 Forecast
Via Benzinga
Why Transcode Therapeutics (RNAZ) Stock Is Down 60%
Via Benzinga
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Crude Oil Down 2%; GE Aerospace Earnings Top Views
Via Benzinga
Exposures Fossil Fuels
US Stocks Edge Higher; General Motors Posts Upbeat Earnings
Via Benzinga
Why Is Mira Pharmaceuticals (MIRA) Stock Down 27% Today?
Via InvestorPlace
Why Is TransCode Therapeutics (RNAZ) Stock Down 62% Today?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Why SAP Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
TransCode Therapeutics, Inc. Announces Pricing of Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
From TransCode Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.